Free Trial

Tejara Capital Ltd Buys 1,344,167 Shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL)

Cardiol Therapeutics logo with Medical background
Remove Ads

Tejara Capital Ltd increased its stake in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) by 75.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,115,437 shares of the company's stock after buying an additional 1,344,167 shares during the period. Cardiol Therapeutics accounts for about 2.6% of Tejara Capital Ltd's portfolio, making the stock its 14th largest holding. Tejara Capital Ltd owned 3.77% of Cardiol Therapeutics worth $3,988,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Townsquare Capital LLC bought a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth about $27,000. Jane Street Group LLC bought a new stake in Cardiol Therapeutics in the 3rd quarter valued at about $29,000. Jones Financial Companies Lllp bought a new stake in Cardiol Therapeutics in the 4th quarter valued at about $25,000. Atria Investments Inc bought a new stake in Cardiol Therapeutics in the 4th quarter valued at about $174,000. Finally, Lion Street Advisors LLC boosted its holdings in Cardiol Therapeutics by 12.6% in the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company's stock valued at $396,000 after purchasing an additional 34,385 shares during the period. Institutional investors own 12.49% of the company's stock.

Cardiol Therapeutics Stock Performance

Shares of Cardiol Therapeutics stock opened at $1.17 on Tuesday. The company has a 50 day moving average of $1.25 and a 200-day moving average of $1.59. Cardiol Therapeutics Inc. has a 1-year low of $1.02 and a 1-year high of $3.12. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01. The company has a market cap of $96.65 million, a PE ratio of -3.00 and a beta of 0.95.

Analysts Set New Price Targets

CRDL has been the subject of a number of recent research reports. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of Cardiol Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $7.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Monday, February 24th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $8.40.

Remove Ads

Read Our Latest Report on CRDL

About Cardiol Therapeutics

(Free Report)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Read More

Institutional Ownership by Quarter for Cardiol Therapeutics (NASDAQ:CRDL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cardiol Therapeutics Right Now?

Before you consider Cardiol Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.

While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

7 Flying Car Stocks to Buy Before the Sector Really Takes Off

Flying cars are coming sooner than you think! Investors are getting excited about this futuristic industry, and MarketBeat analyst Chris Markoch breaks down 7 flying car stocks poised to take off.

Related Videos

Archer Aviation: Sinking Now, Soaring Soon?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
Palantir’s Explosive Growth: Buy Now or Wait for a Dip?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads